Precigen Inc. (NASDAQ:PGEN) finished Wednesday with an addition of $0.09 to close at $1.68, an upside of 5.66 percent. An average of 2,544,880 shares of common stock have been traded in the last five days. There was a gain of $0.1650 in the past week, and it reached a new high 4 times over the past 12 months. The last 20 days have seen an average of 2,212,495 shares traded, while the 50-day average volume stands at 1,683,812.
PGEN stock has increased by 34.40% in the last month. The company shares reached their 1-month lowest point of $1.0600 on 08/07/23. With the stock rallying to its 52-week high on 01/23/23, shares of the company touched a low of $0.81 and a high of $2.90 in 52 weeks. It has reached a new high 10 times so far this year and achieved 10.53% or $0.1600 in price. In spite of this, the price is down -42.07% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
PGEN stock investors should be aware that Precigen Inc. (PGEN) stock had its last reported insider trading activity 6 days ago on Aug 18. In this transaction, the insider spent $92,719. Chief Legal Officer, Lehr Donald P., disposed of 10,762 shares at a price of $1.55 on Aug 17. The insider now owns more than $16,681 worth of shares. Prior to that, Chief Financial Officer Thomasian Harry Jr. went on to Sale 8,893 shares at $1.55 each on Aug 17. An amount of $13,784 was transacted.
Valuation Metrics
Precigen Inc. (PGEN) stock’s beta is 1.86. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 20.75, the price-to-book (PB) ratio at 2.51.
Financial Health
Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Precigen Inc.’s EBITDA margin for the year ending June 29 is -250.53%. Its gross profit as reported stood at $20.57 million compared to revenue of $26.91 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Precigen Inc.’s return on assets was 9.60%.
Earnings Surprise
In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$20.32 million in the quarter, while revenues of -$22.73 million were grew 13.19%. The analyst consensus anticipated Precigen Inc.’s latest quarter earnings to come in at -$0.1 per share, but it turned out to be -$0.08, a 20.00% surprise. For the quarter, EBITDA amounted to -$19.92 million. Shareholders own equity worth $255.48 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Precigen Inc. (PGEN) price momentum. RSI 9-day as of the close on 23 August was 65.75%, suggesting the stock is Neutral, with historical volatility in this time frame at 98.71%.
As of today, PGEN’s price is $1.6420 +10.89% or $0.1650 from its 5-day moving average. PGEN is currently trading +32.28% higher than its 20-day SMA and +66.34% higher than its 100-day SMA. However, the stock’s current price level is +32.28% above the SMA50 and -1.18% below the SMA200.
The stochastic %K and %D were 75.06% and 74.91%, respectively, and the average true range (ATR) was 0.1610. With the 14-day stochastic at 82.12% and the average true range at 0.1494, the RSI (14) stands at 64.00%. The stock has reached 0.0206 on the 9-day MACD Oscillator while the 14-day reading was at 0.1535.
Analyst Ratings
JP Morgan launched coverage on Precigen Inc. (NASDAQ: PGEN) in its analyst report released on May 23, 2023. The firm assigned the stock a Neutral rating. The consensus rating for Precigen Inc. (PGEN) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell PGEN, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 4 others rate it as a “buy”.
What is PGEN’s price target for the next 12 months?
Analysts predict a range of price targets between $6.00 and $14.00, with a median target of $9.00. Taking a look at these predictions, the average price target given by analysts for Precigen Inc. (PGEN) stock is $9.50.
